<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-2018-3-353-364</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-1541</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>РОЛЬ TNFα/TNF-R1-СИГНАЛЬНОГО ПУТИ В РЕАЛИЗАЦИИ ЦИТОТОКСИЧЕСКОГО ЭФФЕКТА ДЕНДРИТНЫХ КЛЕТОК ПРОТИВ ГЛИОБЛАСТОМНЫХ ЛИНИЙ</article-title><trans-title-group xml:lang="en"><trans-title>ROLE OF TNFα/TNF-R1-SIGNALING PATHWAY IN CYTOTOXIC ACTIVITY OF DENDRITIC CELLS AGAINST GLIOBLASTOMA CELL LINES</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тыринова</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Tyrinova</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тыринова Тамара Викторовна – кандидат биологических наук, научный сотрудник лаборатории клеточной иммунотерапии.</p><p>630099, Новосибирск, ул. Ядринцевская, 14, тел.: 8 (383) 228-21-01, факс: 8 (383) 222-70-28</p></bio><bio xml:lang="en"><p>Tyrinova Tamara V. - PhD (Biology), Research Associate, Laboratory of Cellular Immunotherapy.</p><p>630099, Novosibirsk,  Yadrintsevskaya str., 14, phone: 7 (383) 228-21-01, fax: 7 (383) 222-70-28</p></bio><email xlink:type="simple">tyrinova@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мишинов</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Mishinov</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кандидат медицинских наук, врач-нейрохирург отделения нейрохирургии.</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>PhD (Medicine), Clinical Neurosurgeon, Neurosurgery Department</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Леплина</surname><given-names>О. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Leplina</surname><given-names>O. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор медицинских наук, ведущий научный сотрудник лаборатории клеточной иммунотерапии.</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>PhD, MD (Medicine), Leading Research Associate, Laboratory of Cellular Immunotherapy.</p><p>Novosibirsk</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Альшевская</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Alshevskaya</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кандидат медицинских наук, научный сотрудник лаборатории молекулярной иммунологии.</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>PhD (Medicine), Research Associate, Laboratory of Molecular Immunology.</p><p>Novosibirsk </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Курочкина</surname><given-names>Ю. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Kurochkina</surname><given-names>Yu. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аспирант лаборатории клеточной иммунотерапии.</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>Postgraduate Student, Laboratory of Cellular Immunotherapy.</p><p>Novosibirsk </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Олейник</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Oleynik</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аспирант лаборатории клеточной иммунотерапии.</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>Postgraduate Student, Laboratory of Cellular Immunotherapy.</p><p>Novosibirsk</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Калиновский</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kalinovskiy</surname><given-names>А. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кандидат медицинских наук, заведующий операционным блоком.</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>PhD (Medicine), Head, Surgical Unit.</p><p>Novosibirsk</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лопатникова</surname><given-names>Ю. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lopatnikova</surname><given-names>Yu. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кандидат биологических наук, старший научный сотрудник лаборатории молекулярной иммунологии.</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>PhD (Biology), Senior Research Associate, Laboratory of Molecular Immunology.</p><p>Novosibirsk</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чернов</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Chernov</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кандидат медицинских наук, заведующий отделением нейроонкологии.</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>PhD (Medicine), Head, Neurooncology Department.</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ступак</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Stupak</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор медицинских наук, профессор, заведующий отделением нейрохирургии.</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>PhD, MD (Medicine), Professor, Head, Neurosurgery Department</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сенников</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sennikov</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор медицинских наук, профессор, заведующий лабораторией молекулярной иммунологии.</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>PhD, MD (Medicine), Professor, Head, Laboratory of Molecular Immunology.</p><p>Novosibirsk</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Останин</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ostanin</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор медицинских наук, профессор, главный научный сотрудник лаборатории клеточной иммунотерапии.</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>PhD, MD (Medicine), Professor, Main Research Associate, Laboratory of Cellular Immunotherapy.</p><p>Novosibirsk</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Черных</surname><given-names>Е. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Chernykh</surname><given-names>E. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор медицинских наук, профессор, член-корр. РАН, заведующая лабораторией клеточной иммунотерапии.</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>PhD, MD (Medicine), Professor, Corresponding Member, Russian Academy of Sciences, Head, Laboratory of Cellular Immunotherapy.</p><p>Novosibirsk</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ Научно-исследовательский институт фундаментальной и клинической иммунологии</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Institute of Fundamental and Clinical Immunology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «Научно-исследовательский институт травматологии и ортопедии имени Я.Л. Цивьяна» Министерства здравоохранения РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novosibirsk Research Ya.L. Tsivyan Institute of Traumatology and Orthopedics</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБУ «Федеральный центр нейрохирургии» Министерства здравоохранения РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal Neurosurgical Center</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>11</day><month>06</month><year>2018</year></pub-date><volume>20</volume><issue>3</issue><fpage>353</fpage><lpage>364</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Тыринова Т.В., Мишинов С.В., Леплина О.Ю., Альшевская А.А., Курочкина Ю.Д., Олейник Е.А., Калиновский А.В., Лопатникова Ю.А., Чернов С.В., Ступак В.В., Сенников С.В., Останин А.А., Черных Е.Р., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Тыринова Т.В., Мишинов С.В., Леплина О.Ю., Альшевская А.А., Курочкина Ю.Д., Олейник Е.А., Калиновский А.В., Лопатникова Ю.А., Чернов С.В., Ступак В.В., Сенников С.В., Останин А.А., Черных Е.Р.</copyright-holder><copyright-holder xml:lang="en">Tyrinova T.V., Mishinov S.V., Leplina O.Y., Alshevskaya A.A., Kurochkina Y.D., Oleynik E.A., Kalinovskiy А.V., Lopatnikova Y.A., Chernov S.V., Stupak V.V., Sennikov S.V., Ostanin A.A., Chernykh E.R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/1541">https://www.mimmun.ru/mimmun/article/view/1541</self-uri><abstract><p>Дендритные клетки (ДК) больных злокачественными глиомами головного мозга характеризуются нарушением экспрессии мембранной формы TNFα, что ассоциируется с угнетением цитотоксичности ДК против TNF-R1-экспрессирующей опухолевой линии НЕр-2. Чтобы оценить клиническую значимость этого феномена, в настоящей работе исследовалась роль TNFα/TNF-R1сигнального пути в реализации цитотоксической активности ДК против клеток глиобластомных линий, полученных из опухолевой ткани пациентов со злокачественными глиомами головного мозга. ДК генерировали путем культивирования прилипающей фракции МНК в присутствии GM-CSF и IFNα в течение 4 суток с последующим дозреванием с ЛПС в течение 24 ч (IFN-ДК). Опухолевые линии были получены из фрагментов опухоли 11 пациентов с внутримозговой глиобластомой. Показано, что клетки глиобластомных линий чувствительны к цитотоксическому действию IFN-ДК доноров. Выраженность цитотоксического эффекта IFN-ДК против глиобластомных линий, полученных от разных пациентов, варьировала от 20 до 72,2% и в культурах 8 из 11 линий превышала 40%. Клетки глиобластомных линий экспрессировали рецепторы TNF-R1 и TNF-R2, однако экспрессия TNF-R1 была выше. При этом растворимая форма rTNFα не обладала цитотоксическим действием на клетки глиобластомных линий. Блокирование TNFα/TNF-R1-сигнального пути путем обработки IFN-ДК доноров растворимым рецептором rhTNFR1 снижало цитотоксическую активность ДК против 5 из 6 тестируемых глиобластомных линий на 11-40% (медиана супрессии – 24%). ДК больных глиобластомой с дефектом TNFα/TNF-R1-сигнального пути лизировали клетки этих глиобластомных линий, однако медианный уровень цитотоксичности был на 30% ниже, чем аналогичный показатель у доноров (31,5 vs 45,1%; р = 0,003). В то же время цитотоксичность IFN-ДК больного глиобластомой против аутологичных опухолевых клеток единственной линии, резистентной к TNFα/TNF-R1-зависимому пути, была сопоставима с уровнем цитотоксической активности ДК доноров. Таким образом, опухолевые клетки глиобластомных линий чувствительны к цитотоксическому эффекту ДК, опосредованному через TNFα/TNF-R1-сигнальный путь, и дефектность данного механизма у больных детерминирует значимое снижение цитотоксической активности ДК против глиобластомных клеток.</p></abstract><trans-abstract xml:lang="en"><p>Dendritic cells (DCs) of patients with high-grade brain glioma exhibit impaired expression of membrane TNFα associated with low DC cytotoxicity against TNF-R1-expressing tumor cell line HEp-2. To assess the significance of these findings, we investigated a role of TNFα/TNF-R1-signaling pathway in DC cytotoxic activity against allogenic and autologous cell lines obtained from high-grade glioma tissues. DCs were generated by culturing of plastic-adherent peripheral blood mononuclear cells in presence of GM-CSF and IFNα for 4 d followed by LPS addition for 24 h (IFN-DCs). The tumor cell lines were obtained from tissues of 11 patients with glioblastoma multiforme. According our findings glioblastoma cells were sensitive to lysis mediated by donor IFN-DCs. The level of DC cytotoxic effect against cell lines obtained from different glioma patient tissues varied from 20 to 72.2%. DC lysis of 8 out of 11 glioblastoma cell lines exceeded 40%. Glioblastoma cell lines expressed both TNF-R1 and TNF-R2 receptors, but mostly – TNF-R1. However, rTNFα did not show cytotoxic activity towards glioblastoma cell lines. Blocking of TNFα/TNF-R1-signaling pathway by treating of donor IFN-DCs with soluble rhTNFR1 receptor led to partial decrease of DC cytotoxic activity against 5 out of 6 tested glioblastoma cell lines by 11-40% (median of suppression 24%). Glioblastoma patient IFN-DCs which were characterized by an impairment of TNFα/TNF-R1-signaling pathway lysed these glioblastoma cell lines, however median of DC cytotoxicity was 30% lower than that of donor values (31.5 vs 45.1%; р = 0.003). Cytotoxic activity of IFN-DCs of the glioblastoma patient against autologous tumor cells resistance to TNFα/TNF-R1-signaling pathway was comparable with level of cytotoxicity of donor IFN-DCs. Thus, glioblastoma cells are sensitive to cytotoxic activity of DCs mediated via TNFα/TNF-R1-signaling pathway, but the defect of this mechanism in IFN-DCs of glioblastoma patients determines significant decrease of DC cytotoxicity towards glioblastoma cells.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>дендритные клетки</kwd><kwd>интерферон-альфа</kwd><kwd>фактор некроза опухоли альфа</kwd><kwd>TNF-R1</kwd><kwd>глиобластома</kwd></kwd-group><kwd-group xml:lang="en"><kwd>dendritic cells</kwd><kwd>interferon-alpha</kwd><kwd>tumor necrosis factor alpha</kwd><kwd>TNF-R1</kwd><kwd>glioblastoma multiforme</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Тыринова Т.В., Леплина О.Ю., Мишинов С.В., Тихонова М.А., Калиновский А.В., Чернов С.В., Долгова Е.В., Поттер Е.А., Богачев С.С., Ступак В.В., Останин А.А., Черных Е.Р. Нарушение цитотоксической активности дендритных клеток у больных с опухолями головного мозга: механизмы и возможности коррекции // Иммунология, 2016. Т. 37, № 5. С. 246-252.</mixed-citation><mixed-citation xml:lang="en">Tyrinova T.V., Leplina O.Yu., Mishinov S.V., Tikhonova M.A., Kalinovskiy A.V., Chernov S.V., Dolgova E.V., Potter E.A., Bogachev S.S., Stupak V.V., Ostanin A.A., Chernykh E.R. The impairement of cytotoxic activity of dendritic cells in glioma patients: mechanisms and approaches to correction. Immunologiya = Immunology, 2016, Vol. 37, no. 5, pp. 246-252. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nature Reviews Immunology, 2003, Vol. 3, no. 9, pp. 745-756.</mixed-citation><mixed-citation xml:lang="en">Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nature Reviews Immunology, 2003, Vol. 3, no. 9, pp. 745-756.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Bigotti G., Coli A., Castagnola G. Distribution of Langerhans cells and HLA class II molecules in prostatic carcinomas of different histopathological grade. Prostate, 1991, Vol. 19, pp. 73-87.</mixed-citation><mixed-citation xml:lang="en">Bigotti G., Coli A., Castagnola G. Distribution of Langerhans cells and HLA class II molecules in prostatic carcinomas of different histopathological grade. Prostate, 1991, Vol. 19, pp. 73-87.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng S.M., Xing B., Li J. C.B., Cheung B.K.W., Lau A.S.Y. Interferon-γ regulation of TNFα-induced matrix metalloproteinase 3 expression and migration of human glioma T98G cells. The International Journal of Cancer, 2007, Vol. 121, pp. 1190-1196.</mixed-citation><mixed-citation xml:lang="en">Cheng S.M., Xing B., Li J. C.B., Cheung B.K.W., Lau A.S.Y. Interferon-γ regulation of TNFα-induced matrix metalloproteinase 3 expression and migration of human glioma T98G cells. The International Journal of Cancer, 2007, Vol. 121, pp. 1190-1196.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Chuang M.-J., Sun K.-H., Tang S.-J., Deng M.-W., Wu Y.-H., Sung J.-S., Cha T.-L., Sun G.-H. Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. Cancer Science, 2008, Vol. 99, pp. 905-913.</mixed-citation><mixed-citation xml:lang="en">Chuang M.-J., Sun K.-H., Tang S.-J., Deng M.-W., Wu Y.-H., Sung J.-S., Cha T.-L., Sun G.-H. Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. Cancer Science, 2008, Vol. 99, pp. 905-913.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ding Z., Liu Y., Yao L.,Wang D., Zhang J., Cui G., Yang X., Huang X., Liu F., Shen A. Spy1 induces deubiquitinating of RIP1 arrest and confers glioblastoma’s resistance to tumor necrosis factor (TNF-α)-induced apoptosis through suppressing the association of CLIPR-59 and CYLD. Cell Cycle, 2015, Vol. 14, no. 13, pp. 2149-2159.</mixed-citation><mixed-citation xml:lang="en">Ding Z., Liu Y., Yao L.,Wang D., Zhang J., Cui G., Yang X., Huang X., Liu F., Shen A. Spy1 induces deubiquitinating of RIP1 arrest and confers glioblastoma’s resistance to tumor necrosis factor (TNF-α)-induced apoptosis through suppressing the association of CLIPR-59 and CYLD. Cell Cycle, 2015, Vol. 14, no. 13, pp. 2149-2159.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Fanger N.A., Maliszewski C.R., Schooley K., Griffith T.S. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). The Journal of Experimental Medicine, 1999, Vol. 190, pp. 1155-1164.</mixed-citation><mixed-citation xml:lang="en">Fanger N.A., Maliszewski C.R., Schooley K., Griffith T.S. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). The Journal of Experimental Medicine, 1999, Vol. 190, pp. 1155-1164.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Friese M.A., Platten M., Lutz S.Z., Naumann U., Aulwurm S., Bischof F., Buhring H. J., Dichgans J., Rammensee H.G., Steinle A., Weller M. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Research, 2003, Vol. 63, pp. 8996-9006.</mixed-citation><mixed-citation xml:lang="en">Friese M.A., Platten M., Lutz S.Z., Naumann U., Aulwurm S., Bischof F., Buhring H. J., Dichgans J., Rammensee H.G., Steinle A., Weller M. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Research, 2003, Vol. 63, pp. 8996-9006.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Fujikura D., Ito M., Chiba S., Harada T., Perez F., Reed J.C., Uede T., Miyazaki T. CLIPR-59 regulates TNF-α-induced apoptosis by controlling ubiquitination of RIP1. Cell Death and Differentiation, 2012, Vol. 3, e264. doi:10.1038/cddis.2012.3.</mixed-citation><mixed-citation xml:lang="en">Fujikura D., Ito M., Chiba S., Harada T., Perez F., Reed J.C., Uede T., Miyazaki T. CLIPR-59 regulates TNF-α-induced apoptosis by controlling ubiquitination of RIP1. Cell Death and Differentiation, 2012, Vol. 3, e264. doi:10.1038/cddis.2012.3.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Hart D.N. Dendritic cells: unique leukocyte population which control the primary immune response. Blood, 1997, Vol. 90, pp. 3245-3287.</mixed-citation><mixed-citation xml:lang="en">Hart D.N. Dendritic cells: unique leukocyte population which control the primary immune response. Blood, 1997, Vol. 90, pp. 3245-3287.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Janjic B.M., Lu G., Pimenov A., Whiteside T.L., Storkus W.J., Vujanovic N.L. Innate direct anticancer effector function of human immature dendritic cells. I. Involvement of an apoptosis-inducing pathway. The Journal of Immunology, 2002, Vol. 168, pp. 1823-1830.</mixed-citation><mixed-citation xml:lang="en">Janjic B.M., Lu G., Pimenov A., Whiteside T.L., Storkus W.J., Vujanovic N.L. Innate direct anticancer effector function of human immature dendritic cells. I. Involvement of an apoptosis-inducing pathway. The Journal of Immunology, 2002, Vol. 168, pp. 1823-1830.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Jiang Y., Yu M., Hu X., Han L., Yang K., Ba H., Zhang Z., Yin B., Yang X.P., Li Z., Wang J. STAT1 mediates transmembrane TNF-alpha-induced formation of death-inducing signaling complex and apoptotic signaling via TNFR1. Cell Death and Differentiation, 2017, Vol. 24, no. 4, pp. 660-671.</mixed-citation><mixed-citation xml:lang="en">Jiang Y., Yu M., Hu X., Han L., Yang K., Ba H., Zhang Z., Yin B., Yang X.P., Li Z., Wang J. STAT1 mediates transmembrane TNF-alpha-induced formation of death-inducing signaling complex and apoptotic signaling via TNFR1. Cell Death and Differentiation, 2017, Vol. 24, no. 4, pp. 660-671.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kato T., Sawamura Y., Tada M., Sakuma S., Sudo M., Abe H. p55 and p75 tumor necrosis factor receptor expression on human glioblastoma cells. Neurologia Medico-Chirurgica (Tokyo), 1995, Vol. 35, no. 8, pp. 567-574.</mixed-citation><mixed-citation xml:lang="en">Kato T., Sawamura Y., Tada M., Sakuma S., Sudo M., Abe H. p55 and p75 tumor necrosis factor receptor expression on human glioblastoma cells. Neurologia Medico-Chirurgica (Tokyo), 1995, Vol. 35, no. 8, pp. 567-574.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Korthals M., Safaian N., Kronenwett R., Maihöfer D., Schott M., Papewalis C., Diaz Blanco E., Winter M., Czibere A., Haas R., Kobbe G., Fenk R. Monocyte derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis. Journal of Translational Medicine, 2007, Vol. 5, p. 46.</mixed-citation><mixed-citation xml:lang="en">Korthals M., Safaian N., Kronenwett R., Maihöfer D., Schott M., Papewalis C., Diaz Blanco E., Winter M., Czibere A., Haas R., Kobbe G., Fenk R. Monocyte derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis. Journal of Translational Medicine, 2007, Vol. 5, p. 46.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Sh., Yu Y., Zhang M., Wang W., Cao X. The involvement of TNF-α-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-β-stimulated human dendritic cells to tumor cells. The Journal of Immunology, 2001, Vol. 166, no. 9, pp. 5407-5415.</mixed-citation><mixed-citation xml:lang="en">Liu Sh., Yu Y., Zhang M., Wang W., Cao X. The involvement of TNF-α-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-β-stimulated human dendritic cells to tumor cells. The Journal of Immunology, 2001, Vol. 166, no. 9, pp. 5407-5415.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Nabors L.B., Suswam E., Huang Y., Yang X., Johnson M.J., King P.H. Tumor necrosis factor α induces angiogenic factor up-regulation in malignant glioma cells. Cancer Research, 2003, Vol. 63, no. 14, pp. 4181-4187.</mixed-citation><mixed-citation xml:lang="en">Nabors L.B., Suswam E., Huang Y., Yang X., Johnson M.J., King P.H. Tumor necrosis factor α induces angiogenic factor up-regulation in malignant glioma cells. Cancer Research, 2003, Vol. 63, no. 14, pp. 4181-4187.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Sakuma S., Sawamura Y., Tada M., Aida T., Abe H., Suzuki K., Taniguti N. Responses of human glioblastoma cells to human natural tumor necrosis factor-α; susceptibility, mechanism of resistance and cytokine production studies. The Journal of Neuro-Oncology, 1993, Vol. 15, pp. 197-208.</mixed-citation><mixed-citation xml:lang="en">Sakuma S., Sawamura Y., Tada M., Aida T., Abe H., Suzuki K., Taniguti N. Responses of human glioblastoma cells to human natural tumor necrosis factor-α; susceptibility, mechanism of resistance and cytokine production studies. The Journal of Neuro-Oncology, 1993, Vol. 15, pp. 197-208.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Schroder S., Schwarz W., Rehpenninng W., Loning T., Bocker W. Dendritic/Langerhans cells and prognosis in patients with papillary carcinoma. Immunohistochemical study of 106 thyroid neoplasm correlated to follow up data. American Journal of Clinical Pathology, 1988, Vol. 99, pp. 295-300.</mixed-citation><mixed-citation xml:lang="en">Schroder S., Schwarz W., Rehpenninng W., Loning T., Bocker W. Dendritic/Langerhans cells and prognosis in patients with papillary carcinoma. Immunohistochemical study of 106 thyroid neoplasm correlated to follow up data. American Journal of Clinical Pathology, 1988, Vol. 99, pp. 295-300.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Shi W., Li Z.Y., Gong F.L., Xiong P., Xu Y. Comparison of the cytocidal effect induced by transmembrane and secreted TNF-alpha. Chinese Journal of Microbiology and Immunology, 1998, Vol. 18, pp. 499-504</mixed-citation><mixed-citation xml:lang="en">Shi W., Li Z.Y., Gong F.L., Xiong P., Xu Y. Comparison of the cytocidal effect induced by transmembrane and secreted TNF-alpha. Chinese Journal of Microbiology and Immunology, 1998, Vol. 18, pp. 499-504</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Stary G., Bangert C., Tauber M., Strohal R., Kopp T., Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. The Journal of Experimental Medicine, 2007, Vol. 204, pp. 1441-1451.</mixed-citation><mixed-citation xml:lang="en">Stary G., Bangert C., Tauber M., Strohal R., Kopp T., Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. The Journal of Experimental Medicine, 2007, Vol. 204, pp. 1441-1451.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Tyrinova T.V., Leplina O.Y., Mishinov S.V., Tikhonova M.A., Shevela E.Y., Stupak V.V., Pendyurin I.V., Shilov A.G., Alyamkina E.A., Rubtsova N.V., Bogachev S.S., Ostanin A.A., Chernykh E.R. Cytotoxic activity of exvivo generated IFNα-induced monocyte-derived dendritic cells in brain glioma patients. Cell Immunology, 2013, Vol. 284, pp. 146-153.</mixed-citation><mixed-citation xml:lang="en">Tyrinova T.V., Leplina O.Y., Mishinov S.V., Tikhonova M.A., Shevela E.Y., Stupak V.V., Pendyurin I.V., Shilov A.G., Alyamkina E.A., Rubtsova N.V., Bogachev S.S., Ostanin A.A., Chernykh E.R. Cytotoxic activity of exvivo generated IFNα-induced monocyte-derived dendritic cells in brain glioma patients. Cell Immunology, 2013, Vol. 284, pp. 146-153.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Vanderheyde N., Vandenabeele P., Goldman M., Willems F. Distinct mechanisms are involved in tumoristatic and tumoricidal activities of monocyte-derived dendritic cells. Immunology Letters, 2004, Vol. 91, no. 2-3, pp. 99-101.</mixed-citation><mixed-citation xml:lang="en">Vanderheyde N., Vandenabeele P., Goldman M., Willems F. Distinct mechanisms are involved in tumoristatic and tumoricidal activities of monocyte-derived dendritic cells. Immunology Letters, 2004, Vol. 91, no. 2-3, pp. 99-101.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Wischhusen J., Friese M.A., Mittelbronn M., Meyermann R., Weller M. HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. The Journal of Neuropathology and Experimental Neurology, 2005, Vol. 64, pp. 523-528.</mixed-citation><mixed-citation xml:lang="en">Wischhusen J., Friese M.A., Mittelbronn M., Meyermann R., Weller M. HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. The Journal of Neuropathology and Experimental Neurology, 2005, Vol. 64, pp. 523-528.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Wu A., Wiesner S., Xiao J., Ericson K., Chen W., Hall W. A., Low W. C., Ohlfest J. R. Expression of MHC I and NK ligands on human CD133 glioma cells: possible targets of immunotherapy. The Journal of Neuro-Oncology, 2007, Vol. 83, pp. 121-131.</mixed-citation><mixed-citation xml:lang="en">Wu A., Wiesner S., Xiao J., Ericson K., Chen W., Hall W. A., Low W. C., Ohlfest J. R. Expression of MHC I and NK ligands on human CD133 glioma cells: possible targets of immunotherapy. The Journal of Neuro-Oncology, 2007, Vol. 83, pp. 121-131.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
